EDX Medical Group
EDX Medical specializes in creating health testing solutions for medical professionals that improve the rapid detection and characterization of major diseases, enabling personalized treatment and better patient outcomes. The company focuses on oncology, cardiology, and infectious diseases, developing innovative diagnostic tests and digital solutions to set new standards in risk assessment and clinical decision-making.
Industries
Nr. of Employees
small (1-50)
EDX Medical Group
EDX Medical Group plc, 201 Temple Chambers, 3 – 7 Temple Avenue, London, EC4Y ODT
Products
Comprehensive tumour profiling (whole-exome and whole-transcriptome sequencing service)
A laboratory service that performs comprehensive DNA and RNA sequencing and protein analysis to identify molecular biomarkers for precision oncology.
Liquid biopsy molecular profiling and MRD testing service
Blood-based sequencing service for tumour molecular profiling and minimal residual disease monitoring.
Ex vivo functional tumour response assay
Laboratory assay that tests living tumour tissue against therapies to predict sensitivity to chemotherapy, immunotherapy and biological treatments.
Non-invasive early-detection cancer tests (organ-specific panels)
Blood and/or urine-based screening tests under development for early detection of specific cancers (examples cited: testicular, prostate, bowel).
Pharmacogenomic chemotherapy-safety panel (expanded 5‑FU/capecitabine panel)
Genetic test panel to predict severe adverse reactions to fluoropyrimidine chemotherapy by detecting multiple gene variants associated with drug metabolism and toxicity.
Comprehensive tumour profiling (whole-exome and whole-transcriptome sequencing service)
A laboratory service that performs comprehensive DNA and RNA sequencing and protein analysis to identify molecular biomarkers for precision oncology.
Liquid biopsy molecular profiling and MRD testing service
Blood-based sequencing service for tumour molecular profiling and minimal residual disease monitoring.
Ex vivo functional tumour response assay
Laboratory assay that tests living tumour tissue against therapies to predict sensitivity to chemotherapy, immunotherapy and biological treatments.
Non-invasive early-detection cancer tests (organ-specific panels)
Blood and/or urine-based screening tests under development for early detection of specific cancers (examples cited: testicular, prostate, bowel).
Pharmacogenomic chemotherapy-safety panel (expanded 5‑FU/capecitabine panel)
Genetic test panel to predict severe adverse reactions to fluoropyrimidine chemotherapy by detecting multiple gene variants associated with drug metabolism and toxicity.
Services
Provision of tumour and hereditary genetic testing services including whole-exome/transcriptome sequencing, targeted NGS and proteomic analysis for clinical and research use.
Distribution and deployment of rapid bedside and point-of-care diagnostic tests and related devices for use in clinical settings.
Collaborative development of clinical-grade assays with academic groups and industry partners, including in-licensing of biomarker IP and co-development with reagent/instrument suppliers.
Regional exclusive distribution and commercialisation of advanced molecular profiling services provided by third-party laboratories.
Provision of tumour and hereditary genetic testing services including whole-exome/transcriptome sequencing, targeted NGS and proteomic analysis for clinical and research use.
Distribution and deployment of rapid bedside and point-of-care diagnostic tests and related devices for use in clinical settings.
Collaborative development of clinical-grade assays with academic groups and industry partners, including in-licensing of biomarker IP and co-development with reagent/instrument suppliers.
Regional exclusive distribution and commercialisation of advanced molecular profiling services provided by third-party laboratories.
Expertise Areas
- Molecular diagnostics and genomic sequencing
- Liquid biopsy and minimal residual disease testing
- Functional tumour assays for treatment selection
- Point-of-care infectious disease diagnostics
Key Technologies
- Next-generation sequencing (WES/WTS)
- Liquid biopsy (circulating tumour DNA) sequencing
- Proteomics for clinical samples
- Ex vivo tumour culture and functional assays
News & Updates
Professor Sir Chris Evans appeared on The Naked Scientists podcast to discuss a groundbreaking prostate cancer test.
The Independent highlighted EDX Medical's pioneering early detection tests for prostate and testicular cancer.
Professor Sir Chris Evans talks to UK Health Radio about our testicular cancer detection test, TC100
Professor Sir Chris Evans discussed the TC100 test for testicular cancer on UK Health Radio.
Dr Mike Hudson provided insights into EDX Medical’s progress in an interview with StockBox.
EDX Medical announced its participation in the Aquis Showcase Event.
Eric Vick was appointed as Chief Commercial Officer to lead the company's commercial expansion.
Professor Sir Chris Evans appeared on The Naked Scientists podcast to discuss a groundbreaking prostate cancer test.
The Independent highlighted EDX Medical's pioneering early detection tests for prostate and testicular cancer.
Professor Sir Chris Evans talks to UK Health Radio about our testicular cancer detection test, TC100
Professor Sir Chris Evans discussed the TC100 test for testicular cancer on UK Health Radio.
Dr Mike Hudson provided insights into EDX Medical’s progress in an interview with StockBox.
EDX Medical announced its participation in the Aquis Showcase Event.
Eric Vick was appointed as Chief Commercial Officer to lead the company's commercial expansion.